- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
- Drug · Device · Other
- Lead sponsor
- Pharmosa Biopharm Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Hypertension Due to Lung Disease (Disorder)
- Interventions
- L606, Placebo
- Drug
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Chicago, Illinois + 2 more
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
- Interventions
- L606 inhalation suspension
- Combination Product
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more